| 2025-05-07 | +24.2% | earnings | Seeking Alpha | LivaNova beats top-line and bottom-line estimates; raises FY25 outlook |
| 2025-05-07 | +24.2% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2025-02-25 | -15.8% | earnings | Seeking Alpha | LivaNova PLC 2024 Q4 - Results - Earnings Call Presentation |
| 2025-02-25 | -15.8% | earnings | Seeking Alpha | LivaNova PLC reports mixed Q4 results; initiates FY25 outlook |
| 2025-02-25 | -15.8% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2021-11-03 | +14.2% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2025-08-06 | +13.2% | earnings | Seeking Alpha | LivaNova PLC Non-GAAP EPS of $1.05 beats by $0.18, revenue of $352.5M beats by $20.29M |
| 2025-08-06 | +13.2% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2022-05-04 | -12.6% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2024-05-01 | +12.3% | legal | SEC EDGAR | LIVN 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-04-14 | +10.7% | legal | SEC EDGAR | LIVN 8-K: 2.02, 5.02 (SEC Filing) |
| 2023-02-22 | -10.0% | legal | SEC EDGAR | LIVN 8-K: 2.02, 5.02 (SEC Filing) |
| 2023-12-13 | +8.7% | legal | SEC EDGAR | LIVN 8-K: 8.01 and (SEC Filing) |
| 2022-02-23 | +8.2% | legal | SEC EDGAR | LIVN 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-07-28 | +7.7% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2023-11-20 | -7.6% | legal | SEC EDGAR | LIVN 8-K: 8.01 and (SEC Filing) |
| 2023-07-26 | +7.6% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2025-11-05 | -7.4% | earnings | Seeking Alpha | LivaNova raises 2025 revenue growth outlook to 10.5% amid strong cardiopulmonary expansion and Essenz China launch |
| 2025-11-05 | -7.4% | earnings | Seeking Alpha | LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript |
| 2025-11-05 | -7.4% | earnings | Seeking Alpha | LivaNova PLC Non-GAAP EPS of $1.11 beats by $0.19, revenue of $357.8M beats by $15.08M |
| 2025-11-05 | -7.4% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2022-06-14 | -7.0% | legal | SEC EDGAR | LIVN 8-K: 5.02, 5.07 (SEC Filing) |
| 2023-06-16 | +6.9% | legal | SEC EDGAR | LIVN 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-11-12 | +6.4% | news | Stock Titan | LivaNova (NASDAQ: LIVN) sets targets: FCF conversion >80%, adjusted margin >20% - Stock Titan |
| 2024-07-31 | -6.0% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2022-11-02 | +5.8% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2021-11-12 | -5.4% | legal | SEC EDGAR | LIVN 8-K: 8.01 (SEC Filing) |
| 2021-08-16 | +5.0% | legal | SEC EDGAR | LIVN 8-K: 1.01, 1.02, 2.03, 7.01 (SEC Filing) |
| 2024-02-21 | +4.8% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2022-08-03 | -4.5% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2023-10-06 | -4.4% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2021-08-02 | -3.9% | legal | SEC EDGAR | LIVN 8-K: 8.01 and (SEC Filing) |
| 2023-11-01 | -3.8% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2022-07-06 | -3.5% | legal | SEC EDGAR | LIVN 8-K: 1.01, 1.02, 2.03 (SEC Filing) |
| 2025-09-10 | -3.5% | news | Seeking Alpha | LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript |
| 2026-03-18 | +3.4% | news | Zacks | Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength? |
| 2023-12-06 | +3.4% | legal | SEC EDGAR | LIVN 8-K: 8.01 and (SEC Filing) |
| 2026-01-14 | +3.3% | news | Seeking Alpha | LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-14 | +3.3% | legal | SEC EDGAR | LIVN 8-K: 5.02 (SEC Filing) |
| 2026-03-25 | +3.2% | legal | Insider Monkey | LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea |
| 2026-03-25 | +3.2% | legal | Zacks | LivaNova Expands OSA Care With FDA-Approved aura6000 System |
| 2026-03-25 | +3.2% | news | Business Wire | LivaNova to Announce First-Quarter 2026 Results |
| 2026-03-25 | +3.2% | legal | Yahoo Finance | LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea - Yahoo Finance |
| 2021-04-28 | +3.2% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2026-03-13 | +3.1% | news | Yahoo Finance | Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN) - Yahoo Finance |
| 2022-09-12 | +3.0% | analyst | TradingView | LIVN Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-20 | -3.0% | news | Business Wire | Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea |
| 2026-04-20 | -3.0% | news | Stock Titan | Sleep apnea trial tracks a year of gains with LivaNova implant - Stock Titan |
| 2026-01-30 | +3.0% | analyst | Yahoo Finance | LivaNova (LIVN) Upgraded to Overweight by KeyBanc - Yahoo Finance |
| 2021-08-06 | -2.8% | legal | SEC EDGAR | LIVN 8-K: 8.01 and (SEC Filing) |
| 2026-01-20 | +2.8% | news | Stock Titan | Want LivaNova’s 2025 results update? Here’s when to listen live - Stock Titan |
| 2024-10-08 | -2.8% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2025-10-01 | -2.7% | analyst | Seeking Alpha | Doximity, LivaNova downgraded as Goldman Sachs reviews MedTech and Health IT coverage |
| 2026-02-25 | +2.5% | earnings | Seeking Alpha | LivaNova outlines 6%–7% revenue growth for 2026 as core businesses expand and OSA launch nears |
| 2026-02-25 | +2.5% | earnings | Seeking Alpha | LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript |
| 2026-02-25 | +2.5% | earnings | Seeking Alpha | LivaNova PLC 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-25 | +2.5% | earnings | Seeking Alpha | LivaNova PLC Non-GAAP EPS of $0.86 beats by $0.05, revenue of $360.9M beats by $6.59M |
| 2026-02-25 | +2.5% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2026-02-25 | +2.5% | analyst | GuruFocus | LivaNova (LIVN) Sees Price Target Increased by Needham | LIVN St - GuruFocus |
| 2026-02-25 | +2.5% | earnings | Yahoo Finance | LivaNova (LIVN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance |
| 2023-01-06 | -2.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for LivaNova (LIVN) - Zacks Investment Research |
| 2025-08-07 | +2.4% | earnings | Seeking Alpha | LivaNova PLC 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-07 | +2.4% | earnings | Seeking Alpha | LivaNova raises 2025 organic growth outlook to 9%-10% with upgraded guidance for cardiopulmonary and epilepsy |
| 2025-08-07 | +2.4% | earnings | Seeking Alpha | LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript |
| 2025-09-27 | -2.4% | news | simplywall.st | Those who invested in LivaNova (NASDAQ:LIVN) five years ago are up 15% - simplywall.st |
| 2023-09-21 | -2.3% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2025-04-10 | -2.3% | earnings | Seeking Alpha | LivaNova PLC: Excellent Revenue Earner, Some Short-Term Litigation Concerns |
| 2025-04-10 | -2.3% | earnings | Seeking Alpha | LivaNova PLC: Excellent Revenue Earner, Some Short-Term Litigation Concerns (LIVN) - Seeking Alpha |
| 2025-11-15 | -2.2% | analyst | Seeking Alpha | LivaNova PLC (LIVN) Analyst/Investor Day - Slideshow |
| 2025-06-11 | -2.1% | legal | SEC EDGAR | LIVN 8-K: 5.02, 5.07 (SEC Filing) |
| 2022-12-13 | +2.1% | legal | SEC EDGAR | LIVN 8-K: 8.01 and (SEC Filing) |
| 2023-04-18 | +2.1% | executive | Morningstar | LivaNova: Abrupt CEO Resignation Holds Few Surprises as Shares Rise - Morningstar |
| 2025-12-31 | -2.1% | news | AD HOC NEWS | LivaNova stock tests investor patience as Wall Street weighs turnaround against volatility - AD HOC NEWS |
| 2024-02-05 | +2.0% | legal | SEC EDGAR | LIVN 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-07-07 | +1.9% | news | Seeking Alpha | LivaNova: The Sell-Off Is Excessive Here |
| 2025-07-07 | +1.9% | news | Seeking Alpha | LivaNova: The Sell-Off Is Excessive Here (NASDAQ:LIVN) - Seeking Alpha |
| 2023-05-03 | +1.9% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2023-04-21 | -1.9% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2025-09-04 | +1.9% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2024-03-08 | -1.8% | legal | SEC EDGAR | LIVN 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2022-03-21 | -1.7% | legal | SEC EDGAR | LIVN 8-K: 1.01, 2.03, 8.01 (SEC Filing) |
| 2025-10-23 | -1.3% | news | Seeking Alpha | LivaNova: Robust Fundamentals, Long-Term Growth Potential |
| 2026-04-13 | +1.3% | earnings | GlobeNewswire | Drug Resistant Epilepsy Market Insights, Epidemiology, and Forecasts, 2022-2026 & 2026-2036 |
| 2024-03-02 | +1.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-03-26 | +1.2% | legal | Simply Wall St. | Should FDA Approval of aura6000 Sleep Apnea Therapy Require Action From LivaNova (LIVN) Investors? |
| 2026-04-10 | +1.0% | earnings | MarketBeat | Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN - MarketBeat |
| 2025-11-07 | +1.0% | earnings | Seeking Alpha | LivaNova PLC 2025 Q3 - Results - Earnings Call Presentation |
| 2022-09-15 | +1.0% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2023-10-19 | +1.0% | legal | SEC EDGAR | LIVN 8-K: 5.02 (SEC Filing) |
| 2026-03-19 | +0.9% | legal | MT Newswires | LivaNova Says FDA Approves Sleep Apnea Device |
| 2026-03-19 | +0.9% | news | Business Wire | LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea |
| 2026-03-19 | +0.9% | legal | Seeking Alpha | LivaNova gains FDA premarket approval for aura6000 for sleep apnea |
| 2026-03-19 | +0.9% | legal | Stock Titan | New sleep apnea implant wins FDA nod without a collapse warning - Stock Titan |
| 2026-04-04 | -0.9% | earnings | MarketBeat | Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN - MarketBeat |
| 2025-12-07 | -0.8% | earnings | simplywall.st | Improved Revenues Required Before LivaNova PLC (NASDAQ:LIVN) Stock's 26% Jump Looks Justified - simplywall.st |
| 2024-09-10 | -0.7% | legal | SEC EDGAR | LIVN 8-K: 5.02 (SEC Filing) |
| 2025-05-11 | -0.6% | earnings | Seeking Alpha | LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript |
| 2026-02-27 | -0.6% | analyst | Seeking Alpha | LivaNova: Excellent Performer, But Too Expensive In 2026 (Rating Downgrade) |
| 2026-02-27 | -0.6% | analyst | Seeking Alpha | LivaNova: Excellent Performer Too Expensive In 2026 (Rating Downgrade) (NASDAQ:LIVN) - Seeking Alpha |
| 2025-11-13 | -0.5% | analyst | Seeking Alpha | LivaNova PLC (LIVN) Analyst/Investor Day Transcript |
| 2025-10-22 | -0.5% | news | Seeking Alpha | LivaNova: Robust Fundamentals, Long-Term Growth Potential - Seeking Alpha |
| 2025-05-09 | -0.5% | earnings | Seeking Alpha | LivaNova PLC 2025 Q1 - Results - Earnings Call Presentation |
| 2022-12-14 | +0.5% | legal | SEC EDGAR | LIVN 8-K: 5.02 and (SEC Filing) |
| 2025-02-26 | -0.3% | earnings | Seeking Alpha | LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript |
| 2024-10-30 | -0.3% | earnings | Seeking Alpha | LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript |
| 2024-10-30 | -0.3% | earnings | Seeking Alpha | LivaNova PLC 2024 Q3 - Results - Earnings Call Presentation |
| 2024-10-30 | -0.3% | legal | SEC EDGAR | LIVN 8-K: 2.02 and (SEC Filing) |
| 2026-04-17 | +0.2% | news | Zacks | AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains? |
| 2026-04-17 | +0.2% | news | Xã Châu Thành | Best Time to Sell LivaNova PLC (LIVN) Stock (Institutional Selling) 2026-04-16 - Insider Selling - Xã Châu Thành |
| 2026-04-17 | +0.2% | earnings | MarketBeat | LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat |
| 2026-03-20 | +0.2% | legal | Stock Titan | LIVN SEC Filings - Livanova Plc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2025-04-25 | -0.1% | news | Stock Titan | LIVN Stock Price, News & Analysis - Stock Titan |
| 2024-06-12 | -0.0% | legal | SEC EDGAR | LIVN 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-04-25 | — | earnings | MarketBeat | LivaNova (NASDAQ:LIVN) Shares Cross Below 50 Day Moving Average - Here's Why - MarketBeat |